Cara Therapeutics, Inc.·4

Nov 3, 4:37 PM ET

Posner Christopher 4

4 · Cara Therapeutics, Inc. · Filed Nov 3, 2023

Insider Transaction Report

Form 4
Period: 2023-11-02
Posner Christopher
DirectorPRESIDENT AND CEO
Transactions
  • Sale

    Common Stock

    2023-11-02$1.22/sh3,796$4,631164,411 total
Footnotes (1)
  • [F1]This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION